Sathiaseelan Perumal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sathiaseelan Perumal has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Ashish Shah
Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Vadodara, India
3 shared publications - Ghanshyam Parmar
Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Waghodia, Vadodara-391760, Gujarat, India
2 shared publications - Manav Jain
Pediatrics Department, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT 84108, USA
2 shared publications - Aarti Choudhary
Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Vadodara, India
1 shared publication - Aishwarya Anand
Department of Pathology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
1 shared publication - Ashish Patel
Department of Pharmaceutical chemistry, Parul institute of pharmacy, Parul University, Vadodara-391760, Gujarat, India
1 shared publication
Latest Publications
- 18 February 2024
- Published by Springer Nature in 3 Biotech
- Vol. 14 (3) , 1-20
Discovery of novel anticancer flavonoids as potential HDAC2 inhibitors: virtual screening approach based on molecular docking, DFT and molecular dynamics simulations studies
Virtual screening of a library of 329 flavonoids obtained from the NPACT database was performed to find out potential novel HDAC2 inhibitors. Eleven out of 329 selected flavonoids were screened based on molecular docking studies, as they have higher binding affinities than the standard drugs vorinostat and panobinostat. All screened compounds occupying the catalytic site of HDAC2 showed important molecular interaction with Zn2+ and other important amino acids in the binding pocket. The screened compounds were validated using ADMET filtration and bioactivity prediction from which we obtained six compounds, NPACT00270, NPACT00676, NPACT00700, NPACT001008, NPACT001054, and NPACT001407, which were analyzed using DFT studies. DFT studies were performed for all six screened flavonoids. In DFT studies, three flavonoids, NPACT00700, NPACT001008, and NPACT001407, were found to be better based on HOMO–LUMO and molecular electrostatic potential (MEP) analyses. Furthermore, MD simulations were performed for 100 ns for the three compounds. In the MD analysis, NPACT001407 was found to be more stable in the active site of HDAC2 as zinc formed a coordination bond with ASP181, HIS183, ASP269, and GLY305, along with two hydroxyl groups of the ligand. Our findings reveal that these flavonoids can interact as ligands with the active site of HDAC2. Because of the absence of a hydroxamate group in flavonoids, there are no possibilities for the formation of isocyanate. This suggests that the major drawback of current HDACs inhibitors may be solved. Further experimental validation is needed to understand the selectivity of flavonoids as HDAC2 inhibitors.
- 18 February 2024
- Published by Springer Nature in 3 Biotech
- Vol. 14 (3) , 1-20
Discovery of novel anticancer flavonoids as potential HDAC2 inhibitors: virtual screening approach based on molecular docking, DFT and molecular dynamics simulations studies
Virtual screening of a library of 329 flavonoids obtained from the NPACT database was performed to find out potential novel HDAC2 inhibitors. Eleven out of 329 selected flavonoids were screened based on molecular docking studies, as they have higher binding affinities than the standard drugs vorinostat and panobinostat. All screened compounds occupying the catalytic site of HDAC2 showed important molecular interaction with Zn2+ and other important amino acids in the binding pocket. The screened compounds were validated using ADMET filtration and bioactivity prediction from which we obtained six compounds, NPACT00270, NPACT00676, NPACT00700, NPACT001008, NPACT001054, and NPACT001407, which were analyzed using DFT studies. DFT studies were performed for all six screened flavonoids. In DFT studies, three flavonoids, NPACT00700, NPACT001008, and NPACT001407, were found to be better based on HOMO–LUMO and molecular electrostatic potential (MEP) analyses. Furthermore, MD simulations were performed for 100 ns for the three compounds. In the MD analysis, NPACT001407 was found to be more stable in the active site of HDAC2 as zinc formed a coordination bond with ASP181, HIS183, ASP269, and GLY305, along with two hydroxyl groups of the ligand. Our findings reveal that these flavonoids can interact as ligands with the active site of HDAC2. Because of the absence of a hydroxamate group in flavonoids, there are no possibilities for the formation of isocyanate. This suggests that the major drawback of current HDACs inhibitors may be solved. Further experimental validation is needed to understand the selectivity of flavonoids as HDAC2 inhibitors.
- 10 November 2023
- Published by Wiley in ChemistrySelect
- Vol. 8 (42)
Discovery of Small‐Molecule Inhibitors Targeting Progranulin‐Sortilin: An in‐silico Approach Using Molecular Docking, Molecular Dynamics Simulations, and DFT Studies
Introduction : Reduction in progranulin (PGRN) have been associated with various neurodegenerative diseases. PGRN binds with high affinity to sortilin (SORT), a membrane transporter, resulting in its cellular uptake and eventual degradation in the lysosome. Inhibition of the SORT‐PGRN interaction has the potential to increase PGRN levels up to 2.5‐fold. Methodology : A virtual screening of curated CNS library of >47 K ligands was done with sortilin receptor (6X3L) through virtual screening workflow in Schrodinger suite. Co‐crystallised ligand was used as a positive control. Docking was done through HTVS, then SP and finally XP model followed by binding free energy calculations (MMGBSA). Based on the result analysis of molecular docking, binding free energy and interactions, docked complexes were chosen for molecular dynamics (MD) studies. DFT studies and MEP plotting were carried out for the screened ligands. Drug likeliness and ADMET studies were also carried out. Results : The virtual screening workflow yielded 139 ligands. Two test ligands and a control were selected and further evaluated through molecular dynamics studies. Both the test ligands (1625 & 127) had comparative docking score (−5.96 & −6.46 kcal/mol) as that of control ligand (−6.21 kcal/mol respectively) and but better binding free energy (−54.66, −53.12 & −43.21 kcal/mol respectively). MD simulations confirmed the docking results for all the three ligands where our test ligand 1625 reached equilibrium quickly as compared to the rest. Our test compounds also showed favourable characteristics of a CNS acting drug and favourable ADMET properties. According to DFT studies, the test ligands 127 and 1625 had FMO (HOMO‐LUMO) energy gaps of 8.86 eV and 9.83 eV, respectively, that were lesser than the control ligand (9.89 eV). Additionally, FMO energy gap of the test ligands and the control ligand were in agreement with the results of docking. MEP diagram provided the picture of electron rich, neutral and electron deficient surface of the test ligands and that of the control with respective color code red, green and blue. Conclusion : Our study results showed a promising CNS specific ligand as an inhibitor of PRGN‐SORT interactions and has a potential to be developed as a drug through in‐vitro and in‐vivo studies.
- 10 November 2023
- Published by Wiley in ChemistrySelect
- Vol. 8 (42)
Discovery of Small‐Molecule Inhibitors Targeting Progranulin‐Sortilin: An in‐silico Approach Using Molecular Docking, Molecular Dynamics Simulations, and DFT Studies
Introduction : Reduction in progranulin (PGRN) have been associated with various neurodegenerative diseases. PGRN binds with high affinity to sortilin (SORT), a membrane transporter, resulting in its cellular uptake and eventual degradation in the lysosome. Inhibition of the SORT‐PGRN interaction has the potential to increase PGRN levels up to 2.5‐fold. Methodology : A virtual screening of curated CNS library of >47 K ligands was done with sortilin receptor (6X3L) through virtual screening workflow in Schrodinger suite. Co‐crystallised ligand was used as a positive control. Docking was done through HTVS, then SP and finally XP model followed by binding free energy calculations (MMGBSA). Based on the result analysis of molecular docking, binding free energy and interactions, docked complexes were chosen for molecular dynamics (MD) studies. DFT studies and MEP plotting were carried out for the screened ligands. Drug likeliness and ADMET studies were also carried out. Results : The virtual screening workflow yielded 139 ligands. Two test ligands and a control were selected and further evaluated through molecular dynamics studies. Both the test ligands (1625 & 127) had comparative docking score (−5.96 & −6.46 kcal/mol) as that of control ligand (−6.21 kcal/mol respectively) and but better binding free energy (−54.66, −53.12 & −43.21 kcal/mol respectively). MD simulations confirmed the docking results for all the three ligands where our test ligand 1625 reached equilibrium quickly as compared to the rest. Our test compounds also showed favourable characteristics of a CNS acting drug and favourable ADMET properties. According to DFT studies, the test ligands 127 and 1625 had FMO (HOMO‐LUMO) energy gaps of 8.86 eV and 9.83 eV, respectively, that were lesser than the control ligand (9.89 eV). Additionally, FMO energy gap of the test ligands and the control ligand were in agreement with the results of docking. MEP diagram provided the picture of electron rich, neutral and electron deficient surface of the test ligands and that of the control with respective color code red, green and blue. Conclusion : Our study results showed a promising CNS specific ligand as an inhibitor of PRGN‐SORT interactions and has a potential to be developed as a drug through in‐vitro and in‐vivo studies.
- 25 February 2023
- Published by Springer Nature in Chemistry Africa
- Vol. 6 (4) , 1847-1861
Virtual Screening, Molecular Docking Studies and DFT Calculations of Novel Anticancer Flavonoids as Potential VEGFR-2 Inhibitors
- 25 February 2023
- Published by Springer Nature in Chemistry Africa
- Vol. 6 (4) , 1847-1861
Virtual Screening, Molecular Docking Studies and DFT Calculations of Novel Anticancer Flavonoids as Potential VEGFR-2 Inhibitors